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potentials and twitch force were measured in muscle strips ob-
tained from patients and controls. Of the 36 patients, 25 pre-
sented with chronic muscle weakness of varying degrees, up 
to wheelchair-dependence. The weakness was associated with 
intracellular Na+ overload and edema. Older patients revealed a 
vacuolar myopathy or a progressive muscular dystrophy. Weak-
ness, intracellular Na+ overload and edema were increased and 
further raised by cooling and glucose/insulin, and almost com-
pletely normalized by 4 weeks of treatment with the carbonic 
anhydrase inhibitor acetazolamide (Jurkat-Rott et al., 2009). In 
vitro, the chronic weakness correlated to membrane depolariza-
tion, and acetazolamide repolarized the membrane and restored 
force. We conclude that membrane depolarization associated 
with intracellular Na+ overload and edema causes both episodic 
and permanent muscle weakness. The chronic weakness is re-
versible in muscles which show mild or only moderate fatty de-
generation. Acetazolamide has direct and beneficial effects on 
weak muscle and can markedly improve both forms of weak-
ness.
In  addition,  we  tested  whether  the  edema  in  Duchenne 
muscular  dystrophy  (DMD)  is  caused  by  an  osmotic  effect 
due to increased myoplasmic Na+ content or by inflammation. 
The muscle edema was quantified on STIR images using back-
ground noise as reference. Na+ was quantified by a muscular 
tissue sodium concentration (TSC) sequence. A novel inversion-
recovery (IR) sequence allowed us to determine mainly the my-
oplasmic Na+ by suppression of the extracellular 23Na signal, 
e.g. from vasogenic edema. Both intracellular TSC and water 
content were markedly increased in DMD compared to volun-
teers (p < 0.001). We conclude that the elevated myoplasmic 
Na+ concentration in DMD is osmotically relevant and causes a 
mainly intracellular muscle edema that contributes to the patho-
genesis of DMD.
We hypothesize that antiedematous treatment can reverse 
the edema and prevent the edema-induced muscle degenera-
tion.
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Central core disease (CCD) and malignant hyperthermia 
(MH) have been linked to point mutations in the gene encod-
ing the skeletal muscle sarcoplasmic reticulum calcium release 
channel  (ryanodine  receptor),  which  is  localized  on  human 
chromosome 19 (RYR11). Central core disease is a relatively 
mild, slowly progressive autosomal dominant myopathy, char-
acterized  histologically  by  the  presence  of  centrally  located 
cores running the length of the muscle fibres. MH is a pharma-
cogenetic induced hypermetabolic disease. CCD linked RyR1 
mutations are associated with depletion of thapsigarin-sensitive 
stores and to an increase of the resting calcium level. Influx of 
Ca2+ from the extracellular environment is a major factor influ-
encing the level of the resting intracellular [Ca2+]. Our work-
ing hypothesis is that decrease of sarco(endo)plasmic reticulum 
Ca2+ load via leaky ryanodine receptor channels and/or altera-
tion of calcium influx via store operated channels or excitation-
coupled Ca2+ entry (ECCE), may account for, at least in part, 
the phenotype of patients with CCD, including muscle weak-
ness and abnormal secretion of inflammatory cytokines from 
muscle cells. We set out to test the validity of our hypothesis by 
directly investigating the mechanisms activating calcium influx 
in myotubes from normal individuals and from patients with 
CCD and MH by TIRF microscopy. Our data shows that some 
mutations in RYR1 affect ECCE in human myotubes from CCD 
and MH patients; this enhanced Ca2+ entry is accompanied by 
the generation of reactive nitrogen species and enhanced nu-
clear localization of NFATc1, which in turn may be responsible 
for the increased IL-6 released by myotubes from patients with 
central core disease.
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